BDBM109762 US8609708, 50 Anatabine

SMILES C1N[C@@H](CC=C1)c1cccnc1

InChI Key InChIKey=SOPPBXUYQGUQHE-UHFFFAOYSA-N

Data  1 KI  1 IC50  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 109762   

TargetNeuronal acetylcholine receptor subunit alpha-4/beta-2(Rat)
University of Auckland

Curated by ChEMBL
LigandPNGBDBM109762(US8609708, 50 Anatabine)
Affinity DataKi:  249nMAssay Description:Displacement of 3H-cytisine from Sprague-Dawley rat brain alpha4beta2 nAChR by liquid scintillation counting methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetNeuronal acetylcholine receptor subunit alpha-4/beta-2(Human)
University of Auckland

Curated by ChEMBL
LigandPNGBDBM109762(US8609708, 50 Anatabine)
Affinity DataEC50:  2.65E+3nMAssay Description:Agonist activity at human brain alpha4beta2 nAChR expressed in Xenopus laevis oocytes assessed as peak responseMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytochrome P450 2A6(Human)
Human Biomolecular Research Institute

US Patent
LigandPNGBDBM109762(US8609708, 50 Anatabine)
Affinity DataIC50: 2.30E+4nMAssay Description:The inhibition of human CYP2A6-mediated 7-hydroxy coumarin formation was evaluated in the presence of 95 selected test compounds in a standard assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/16/2014
Entry Details
US Patent

TargetNeuronal acetylcholine receptor subunit alpha-7(Human)
University of Auckland

Curated by ChEMBL
LigandPNGBDBM109762(US8609708, 50 Anatabine)
Affinity DataEC50:  6.97E+4nMAssay Description:Agonist activity at human brain alpha7 nAChR expressed in Xenopus laevis oocytes assessed as peak responseMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed